The ECHO study results 1 have been widely misreported in the media. This open-label randomised trial was designed primarily to detect whether a difference of at least 50% in HIV-1 risk occurs between three contraceptive methods. Because of the absence of a no contraception control group, the results do not inform on absolute risk of HIV-1 infection for any of the methods. Whether the levonorgestrel (LNG) implant or copper intrauterine device (IUD) increase HIV-1 risk is unknown, although plausible biological mechanisms have been reported. 2 The study did not show that no difference in risk occurred between methods. 3 The results contain considerable uncertainty and both of the analysis methods have inherent limitations 4 because of potential post-initiation confounding factors. The choice of the 50% threshold is highly contentious and hard to justify. If either copper IUD or LNG implant are associated with, for example, a 10% increased HIV-1 risk, and depot medroxyprogesterone acetate (DMPA) is associated with a 40-50% increased HIV-1 risk, then the relative risk between DMPA and either of the other two methods would have been 27-36%-ie, well below the 50% threshold. Results for two of the three comparisons fell in a grey zone, where they could neither rule out a finding of no difference nor a 50% increase. These results suggest that the LNG implant might be a safer option than DMPA and copper IUD. We do not have great scientific certainty as to whether DMPA increases HIV-1 risk by 40-50% relative to no contraception or infre quent condom use, as suggested by meta-analyses of observational data, 5 
